ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable investors across the United States and Asia. The financing will support the continued expansion of ChemT's AI and experimental infrastructure, which aims to make advanced...
STARTRADER Delivers Emergency Relief to 300 Earthquake-Affected Families in the Philippines
Aid initiative supports families in Sarangani Province following the 7.8-magnitude earthquake, reinforcing the importance of collective action during times of crisis. DUBAI, UAE, June 22, 2026 /PRNewswire/ -- STARTRADER, through its charitable arm STARCARES, is delivering emergency relief to 300 families displaced by the 7.8-magnitude earthquake that struck Sarangani Province in...
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. This milestone reflects the Company's long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness. Through robust governance, quality...
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully convened, bringing together regulatory, industry and innovation leaders to discuss the development of China's innovative pharmaceutical...
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment completed; follow‑up phase) and a Phase II study...
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates...
FDA Clears PanopticAI’s Contactless Respiratory Rate Measurement
Following the startup's first FDA 510 (k) clearance for its contactless pulse rate monitoring, PanopticAI has now secured a second one for respiratory rate measurement. This milestone cements its position as the world leader in camera-based physiological measurement, bringing the industry closer to a future where clinical-grade health monitoring is accessible to anyone with a smartphone. HONG KONG,...
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106;...
LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
INCHEON, South Korea and SAN DIEGO, June 22, 2026 /PRNewswire/ -- LOTTE Biologics announced that it has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea. LOTTE Biologics Songdo Bio Campus Factory 1 The milestone was achieved...
Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
SYDNEY and AUCKLAND, New Zealand, June 22, 2026 /PRNewswire/ -- Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne,...
